2010
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis
Karim Q, Karim S, Baxter C, Friedland G, Gengiah T, Gray A, Grobler A, Naidoo K, Padayatchi N, El-Sadr W. The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal 2010, 100: 808-809. PMID: 21414268, DOI: 10.7196/samj.4621.Peer-Reviewed Original Research
2009
Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet Infectious Diseases 2009, 9: 153-161. PMID: 19246019, DOI: 10.1016/s1473-3099(09)70041-6.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsClinical Trials as TopicDirectly Observed TherapyHumansTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisTreatment outcomesHIV statusTreatment regimensStrong patient supportProportion of patientsPatient's HIV statusTuberculosis treatment programmesHigher treatment successSuccessful treatment outcomePublic health concernStandardised regimensMDR tuberculosisObserved therapyPatient populationTreatment completionTreatment successInclusion criteriaPatient supportTherapeutic studiesClinical reportsTreatment approachesTreatment durationPatientsSystematic review
2002
Report on the XIV International AIDS Conference.
Abdool Karim SS, Currier J, del Rio C, Feinberg J, Friedland GH, Sax PE, Zuger A. Report on the XIV International AIDS Conference. Infectious Diseases 2002, 14: 77-85. PMID: 12236208.Peer-Reviewed Original ResearchThe Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials
Mannheimer S, Friedland G, Matts J, Child C, Chesney M, AIDS T. The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials. Clinical Infectious Diseases 2002, 34: 1115-1121. PMID: 11915001, DOI: 10.1086/339074.Peer-Reviewed Original ResearchConceptsHIV RNA levelsHuman immunodeficiency virusImmunodeficiency virusClinical trialsRNA levelsPlasma HIV RNA levelsBiologic outcomesConsistency of adherenceCopies/mLMulticenter clinical trialAntiretroviral therapyCD4 countMonth 12Nonwhite racePoor adherenceAdherence levelsAdherence patternsOlder ageGood adherenceAdherenceCells/TrialsVisitsOutcomesParticipants